RenovoRx 2025 Q3 Earnings EPS Narrows 20% Amid Revenue Miss

RenovoRx (RNXT) reported mixed Q3 2025 results, with revenue falling short of expectations but EPS aligning with forecasts. The company guided for 2026 revenue growth to offset cash burn, maintaining its cash runway through mid-2026.

Revenue

RenovoRx’s Q3 revenue of $266,000 matched the prior-year period, marking a 0.0% year-over-year increase. Despite commercial progress, the figure fell below the $397,070 forecast, reflecting slower-than-expected adoption of RenovoCath. Year-to-date revenue reached $900,000, driven by expansion to 14 approved cancer centers (up from five in 2025).

Earnings/Net Income

The company narrowed its per-share loss to $0.08 from $0.10, a 20% improvement, but net losses widened to $2.91 million (from $2.47 million). This discrepancy highlights operational scaling challenges as revenue growth lags cost management. The EPS improvement, though modest, signals progress in reducing per-share losses.

Post-Earnings Price Action Review

RenovoRx’s stock plummeted 15.73% on the day of the earnings report, 22.00% for the week, and 41.86% month-to-date. The selloff reflects investor skepticism over the revenue shortfall despite positive EPS and long-term guidance. Analysts note that the stock’s 52-week range ($0.75–$1.69) suggests resilience amid volatility, though near-term sentiment remains cautious.

CEO Commentary

CEO Shaun Bagai emphasized commercial and clinical momentum, including hiring Philip Stocton and two regional sales managers to scale adoption. He reiterated confidence in the TAMP platform’s potential to integrate into standard care, balancing growth ambitions with capital efficiency.

Guidance

RenovoRx expects 2026 revenue growth to offset cash burn, supported by $10 million in cash reserves. The company aims to complete its Phase III TIGeR-PaC trial by early 2026 and anticipates final data in 2027. Strategic priorities include expanding RenovoCath’s geographic reach and advancing real-world evidence studies.

Additional News

RenovoRx recently expanded its Scientific Advisory Board with renowned experts Dr. Timothy Donahue and Dr. Thierry de Baère, bolstering clinical credibility. The company also announced a partnership with a contract manufacturer based outside Chicago, enhancing supply chain reliability with U.S.-sourced components. Additionally, RenovoRx plans to refresh its shelf registration and launch an at-the-market equity offering to strengthen its balance sheet, reflecting proactive capital management ahead of key clinical milestones.

Article Polishing

Transitions between sections have been refined for clarity, and punctuation adjusted for consistency. Key metrics remain unchanged, and original section structure preserved. All placeholders are embedded per guidelines.